drugset
drugset / Trial / NCT00659685

Bioavailability Study of Ondansetron 16 mg Orally Disintegrating Tablets Under Fasting Conditions

NCT00659685 ↗

Phase 1 Completed 24 enrolled Par Pharmaceutical, Inc. Algorithme Pharma Inc · collab
RandomizedCrossoverOpen-label

Summary

Single-dose cross over comparative bioavailability of Ondansetron 16 mg ODT and Zofran 16 mg ODT

Timeline

Start
2003-11
Primary completion
—
Completion
—

Drugs

EvaluationDrugModalityDoseRoute
Subject Ondansetron Other / unclassified 16 mg Oral

Indications

No indication recorded.